On October 16, 2025, Iterum Therapeutics plc announced a prospectus to sell up to $20 million of its ordinary shares as part of an at-the-market offering, having previously raised approximately $36.2 million. The company also highlighted the commercial launch of its product ORLYNVAH™ with modest sales expected in 2025.